Project Grant R01AI192632
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $449K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $857,346 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Fred Hutchinson Cancer Center. The grant, awarded on January 17, 2025, supports research to define the activating and inhibitory signals in the form of cytokines and metabolites that are present in healthy and infected human tissues to regulate the effector function of CD8 T cells. This research aims to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $862,398 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Fred Hutchinson Cancer Center in Seattle, WA. The grant, running from August 1, 2025 to July 31, 2030, will support research to selectively target and eliminate the HIV/SIV reservoir in T follicular helper cells using novel anti-PD-1 chimeric antigen receptor (CAR) T cells. The research aims to develop safer and more...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $950,092 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The grant aims to develop two innovative vaccine candidates to prevent pulmonary nontuberculous mycobacterial (NTM) infections, which have surpassed tuberculosis as a global health concern. The research involves screening 13 vaccine...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $189,790 to Northeastern University to develop novel statistical and machine learning methods that characterize heterogeneity in individual vaccine responses. The long-term objective is to advance vaccine efficacy (VE) studies by improving the robustness and applicability of VE estimates across different populations....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
- This $1,486,800 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to investigate the unexpected role of TNFRSF14 signaling in promoting antibody-dependent cell-mediated cytotoxicity (ADCC) for vaccine development against Herpes Simplex Virus (HSV). The research involves engineering a novel single-cycle HSV vaccine strain, isolating potent...
- This $220,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) will support research at the Fred Hutchinson Cancer Center in Seattle, Washington. The project aims to use a novel cell lineage tracing method called ASAP-seq to identify and characterize HIV-specific memory natural killer (NK) cells in a cohort of HIV-infected women. This will help elucidate the role of NK...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...